The U.S. Court of Appeals for the Third Circuit on Sept. 7 opened the door for indirect drug purchasers to recover damages under federal antitrust laws, ruling that the plaintiff in a product-hopping suit had standing to give the courts subject matter jurisdiction over its claims.
In Hartig Drug v. Senju Pharmaceutical, a three-member panel of the appeals court found that Hartig Drug Co., which had purchased two eye care products from pharmaceutical provider AmerisourceBergen Corp., had established a “judicially-redressable” injury when it claimed that Senju Pharmaceutical Co. and its co-defendants suppressed generic versions of Zymar and Zymaxid, resulting in inflated prices for the eye drops.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
